Abstract The structural and functional neuroimaging of dementia have substantially evolved over the last few years. The most common forms of dementia, Alzheimer disease (AD), Lewy body dementia (LBD) and fronto-temporal lobar degeneration (FTLD), have distinct patterns of cortical atrophy and hypometabolism that evolve over time, as reviewed in the first part of this article. The second part discusses unspecific white matter alterations on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images as well as cerebral microbleeds, which often occur during normal aging and may affect cognition. The third part summarises molecular neuroimaging biomarkers recently developed to visualise amyloid deposits, tau protein deposits and neurotransmitter systems. The fourth section reviews the utility of advanced image analysis techniques as predictive biomarkers of cognitive decline in individuals with early symptoms compatible with mild cognitive impairment (MCI). As only about half of MCI cases will progress to clinically overt dementia, whereas the other half remain stable or might even improve, the discrimination of stable versus progressive MCI is of paramount importance for both individual patient treatment and patient selection for clinical trials. The fifth and final part discusses the interindividual variation in the neurocognitive reserve, which is a potential constraint for all proposed methods.
Introduction
This review deals with the current state of neuroimaging of neurodegenerative diseases, especially dementias, seen from a radiologist's perspective. Initially it will review the basic radiological findings in dementias including specific patterns of atrophy, "unspecific" T2/FLAIR lesions and microbleeds. It will provide, as a comparison, the main findings of molecular imaging using nuclear medicine methods, i.e. positron emission tomography (PET) and single photon emission computed tomography (SPECT). It will provide an outlook for molecular biomarkers able to visualise amyloid deposits, tau protein deposits, various neurotransmitter systems and neuroinflammatory phenomena and a discussion of advanced image analysis tools, which are or will probably become available for clinical assessment in the near future. Then, this review will discuss an advanced image analysis tool able to detect subtle morphometric alterations that remain visible to the human eye. Finally, the interindividual variation of the neurocognitive reserve will be reviewed, which potentially interferes with all the neuroimaging techniques discussed. The complex and evolving concept of progressive neurodegeneration including the preclinical phase, especially Alzheimer disease (AD) (e.g. the review article by Lazarczyk et al. [1] ), goes beyond the scope of this review article, which is intended as a practical guide for radiologists.
Patterns of focal atrophy in common forms of dementia
The main objective of neuroimaging in dementia has been and remains the exclusion of other causes of dementia, especially treatable ones, such as normal pressure hydrocephalus, subdural haematomas or neoplasms including meningioma. Nevertheless, many (but not all) common forms of dementia are associated with typical patterns of focal atrophy, which will be discussed in the following section. Radiologists should be aware of these patterns in order to contribute to a specific diagnosis of dementia.
Alzheimer disease
Alzheimer disease (AD) is the most common form of dementia accounting for approximately 60-70 % (www.mghradrounds. org). The typical pattern of atrophy consists of atrophy of the hippocampus with consequent dilatation of the temporal horns of the lateral ventricles, associated with biparietal atrophy (as illustrated in Fig. 1 ). 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) typically shows a reduced glucose metabolism mainly in the posterior cingulate and precuneus and in the parieto-temporal regions (Fig. 1) , probably owing to a combination of atrophy and hippocampal-neocortical disconnection phenomena [2] . These changes may appear early in the disease course, even in patients with a diagnosis of mild cognitive impairment (MCI) and earlier than hippocampal atrophy on morphological imaging.
Posterior cortical atrophy
Posterior cortical atrophy (PCA) is a rare type of dementia characterised by rapid and relatively selective decline in vision while memory and language skills are relatively preserved. PCA is considered by most authors as a variant of AD, with a characteristic atrophy and hypometabolism of the occipital lobe, which is often asymmetric (as illustrated in Fig. 2 ).
Dementia with Lewy bodies
Dementia with Lewy bodies (DLB) is the second most common type of dementia 25 % (www.mghradrounds.org). However, as there is no accepted specific pattern of atrophy (at least for visual inspection), radiologists cannot contribute to the diagnosis. As a consequence, radiologists may underestimate the high prevalence of this type of dementia. Molecular imaging, however, plays a key role in supporting the clinical diagnosis of DLB. FDG-PET shows a typical pattern of hypometabolism, which involves the occipital cortex and typically spares the metabolism of the posterior cingulate cortex ("cingulate island sign"), as shown in Fig. 3 [3] . Additionally the imaging of dopamine transporters, usually performed using SPECT and 123 I-ioflupane, shows that the nigro-striatal pathway is affected. This diagnostic test has a high sensitivity and specificity for the differential diagnosis of DLB vs. non-DLB dementias such as AD or vascular dementia (VaD): in the latter, the density of dopamine transporters is not reduced and 123 I-ioflupane uptake is preserved [4] . The normal distribution of 123 I-ioflupane is a "comma"-shaped uptake in the basal ganglia, whereas the pathologically reduced uptake in the putamen, with activity confined to the head of the caudate nucleus, results in a "punctuation"-shaped uptake (Fig. 3) .
Vascular dementia
Vascular dementia (VaD) is almost as prevalent as DLB (20 %, www.mghradrounds.org). VaD is characterised by confluent signal alterations of the white matter (WM) visible either as hypodensities on CT (as illustrated in Fig. 1 ) or hyperintense signal on T2/FLAIR MRI. In clinical routine, most patients have a combination of neurodegenerative dementia, e.g. AD, and a vascular component, as vascular changes are very Fig.2 Typical focal atrophy of the occipital lobe, which is often asymmetric, as in this case, and more pronounced on the right hemisphere. Note also the concomitant white matter abnormalities. FDG-PET metabolism shows the hypometabolism of the occipital cortex in addition to the involvement of posterior cingulate and temporo-parietal cortices in patients with posterior cortical atrophy (PCA) Fig.1 Typical examples of Alzheimer disease (AD) (top) and vascular dementia (VaD) (bottom). Typical non-enhanced axial CT of an AD patient with focal atrophy of the hippocampus leading to dilation of the temporal horns of the lateral ventricles (arrows) and subtle biparietal atrophy. FDG-PET images show the typical hypometabolism of the posterior cingulate gyrus/precuneus and of the parietal and temporal cortex, bilaterally. These changes are visible on radioactivity distribution images and are significant in comparison with a normal database using BRASS® software (see Sect. "Advanced image analyses" for details). Typical example of VaD with confluent signal alterations of the white matter. Note that in contrast to the AD patient ( Fig. 1) of the same age, there is no focal atrophy of the peri-hippocampal region. FDG-PET images usually show preserved uptake in the posterior cingulate gyrus and focal hypometabolism, corresponding to vascular lesions common during aging. Having a neurodegenerative disease is obviously not protective against concomitant vascular disease.
Fronto-temporal lobar degeneration
Fronto-temporal lobar degeneration is a heterogeneous group of dementias. Moreover, terminology and classification have changed over the last few years and different classifications exist. For the purpose of this review, and in order to avoid misunderstandings, the term fronto-temporal lobar degeneration (FTLD) will be used for the entire group of dementias. Note that some authors use fronto-temporal dementia (FTD) as a term for the entire group, whereas others use this term as a subgroup of dementias including Pick's disease (PiD). To avoid misunderstandings, some authors use the term behavioural variant FTD (bvFTD) to unambiguously refer to the subgroup of dementias. Other subgroups of FTLD are progressive nonfluent aphasia (PNFA) and semantic dementia (SD). Some authors additionally consider progressive supranuclear palsy syndrome (PSPS) and cortico-basal syndrome (CBS) in the group of FTLD, both primarily neurodegenerative motor diseases yet sometimes with associated dementia, which can occasionally be the leading symptom [5] (Fig. 4) . bvFTD has characteristic atrophy and hypometabolism visible on FDG-PET images in both the frontal and anterior temporal lobes, with a characteristic anterior to posterior gradient. Note that images are acquired in the supine position. The brain is heavier than the cerebrospinal fluid and consequently in a declining occipital position. The occipital lobe is "squeezed" against the occipital bone, whereas the frontal lobe is floating in the cerebrospinal fluid and seems to open up. Therefore, neuroimaging typically overestimates frontal atrophy yet underestimates occipital atrophy.
PNFA typically has a bilateral peri-insular atrophy, and asymmetric left frontal and temporal hypometabolism.
SD is characterised by anterior temporo-polar atrophy and hypometabolism usually more pronounced on the left hemisphere, although right-dominant forms also exist.
Progressive non-fluent aphasia and semantic dementia are sometimes collectively called primary progressive aphasia (PPA). Logopaenic aphasia (LPA) has recently been described as a third subtype of PPA characterised by impaired word retrieval and sentence repetition yet intact motor speech and grammar [6, 7] . The atrophy typically predominates in left inferior frontal and posterior temporal regions [8] . Note that although LPA is considered a third variant of PPA, it is probably a variant of AD as opposed to the FTLD variants PNFA and SD. This is also supported by the finding of left parietal and posterolateral temporal lobe hypometabolism and positivity to amyloid PET imaging in these patients [9] . This rare form of dementia is not discussed in further detail in this review.
Although a detailed anatomical cortical measurement might reasonably well discriminate the main subtypes of FTLD [10] , the imaging appearance of these forms of dementia, i.e. bvFTD, PNFA and SD, are variable, with considerable overlap [5] . A radiologist should thus detect if the atrophy of a given patient has a focal predominance in the frontal and laterotemporal regions with an anterior to posterior gradient and open the differential diagnosis of FTLD without insisting on a specific subgroup diagnosis.
PSP is primarily a neurodegenerative movement disorder characterised by a pattern of atrophy notably of the midbrain leading to the penguin or hummingbird sign [11] , which can be quantified using for example the MR parkinsonism index [12] . A subgroup of PSP patients develop neurocognitive decline and in some cases the cognitive impairment may even be the leading symptom. FDG-PET images show a typical cortical hypometabolism in the whole prefrontal cortex, associated with hypometabolism in the basal ganglia, thalamus and mesencephalon.
CBD is, similar to PSP discussed above, primarily a neurodegenerative movement disorder involving cortico-basal degeneration, yet a subgroup of patients develop neurocognitive decline. In analogy to PSP discussed above, the cognitive impairment may be the leading symptom in some cases. CBS typically has a focal biparietal atrophy. Unlike AD, biparietal focal atrophy is not associated with peri-hippocampal atrophy but sometimes with infratentorial cerebellar atrophy. FDG-PET images typically show a unilateral or strongly asymmetric cortical (parietal, prefrontal and motor cortex) and subcortical hypometabolism, contralateral to the affected body side.
Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation (NBIA) is a rare group of diseases with an estimated incidence of 1-3/1,000,000 characterised by brain iron accumulation notably in the basal ganglia. Pantothenate kinase-associated neurodegeneration (PKAN), formally known as HallervordenSpatz syndrome, is the most widely known disease of this group. It is caused by a mutation of the PANK-2 gene (pantothenate kinase) at chromosome 20p13. Other forms include infantile neuroaxonal dystrophy (INAD), neuroferritinopathy, aceruloplasminaemia, Kufor-Rakeb disease (KRD), fatty acid hydroxylase-related neurodegeneration (FAHN) as well as a group of idiopathic NBIA of (still) unknown origin. These conditions show a wide clinical and pathological spectrum including spastic paraplegias, leukodystrophies and neuronal ceroid lipofuscinosis. Imaging appearance is also variable. The typical imaging sign called the "eye of the tiger" consists of a central hyperintensity of the globus pallidus with surrounding hypointensity on T2w images, and can be identified in most cases of PKAN [13] . Although NBIA in most cases is a disease of infants and children with extrapyramidal movement disorders, adult forms of NBIA exist and sometimes dementia may be the leading symptom. Therefore this condition, even though generally a rare cause of dementia, is briefly mentioned in this review.
"Non-specific" white matter T2/FLAIR lesions and normal aging Hyperintense signal alterations of the WM on T2 and FLAIR images are very common findings in the elderly (a typical example is illustrated in Fig. 5 ). These "unspecific" WM lesions, sometimes also called unspecific bright objects (UBOs), have a prevalence of about 15 % at the age of 60, and around 80 % at the age of 80 [14] [15] [16] . Generally speaking, these "unspecific" WM lesions are associated with an increased risk of cognitive decline and dementia, stroke and even death [16, 17] . When looking at the correlation between T2w lesions and neurocognitive decline in more detail, however, it becomes more controversial. For example, only five out of eight studies found an association between WM hyperintensities and global cognitive decline, whereas the remaining three studies were negative [16] . This might be attributed to the inter-individual variation of the cognitive reserve (discussed in detail in Sect. "Neurocognitive reserve mechanisms and imaging biomarkers") [18] . The correlation between radiological WM lesions and histopathology is no less controversial. Despite the very frequent observation of WM hyperintensities on MRI, radiological-pathological correlation studies, especially in combination with pre-mortem MRI, are rare [19] . Histopathological correlates of T2w hyperintensities are very heterogeneous [20] and include myelin pallor, tissue rarefaction including loss of myelin and axons as well as mild gliosis [16, [21] [22] [23] [24] . A recent investigation [25] correlated pre-mortem WM hyperintensities with post-mortem MRI in 59 healthy elderly persons and found that MRI overestimates periventricular lesions yet underestimates deep WM lesions with respect to histopathological demyelination. This might be due to the relatively high local water content in the periventricular lesions in combination with increasing blood-brain barrier permeability which occurs during aging [26] and which tends to cause T2 and FLAIR hyperintense signal on MRI compared with the deep WM which has a relatively lower local water content. Correspondingly, whereas most correlation studies assess global WM lesion load, some studies separately assessed periventricular and deep WM lesions and indicate higher clinical relevance of deep versus periventricular T2-weighted hyperintensities [15, 27] . Future correlation studies are necessary, ideally combining multiple imaging contrasts including T2/FLAIR, diffusion tensor imaging (DTI) and magnetisation transfer, in order to better describe and understand the histopathological correlates of WM lesions detected on MRI. 
Cerebral microbleeds
Cerebral microbleeds (CMB) or cerebral microhaemorrhages (CMH) are small hypointense lesions seen on susceptibility imaging with variable cut-off size in the literature typically between 5 and 10 mm [28] [29] [30] [31] (see Fig. 6 for an example of hypertensive microbleeds). CMBs have attracted growing interest in recent years. This may at least partly be explained by the wide availability of high-field MRI systems and novel imaging sequences, in particular susceptibility-weighted imaging (SWI), as these technical developments increase the number of detectable microbleeds [32] . For example, SWI identified significantly more CMBs than T2* in 141 patients in a memory clinic setting [29] . This increase in detection rate of 40 % in SWI versus 23 % in T2* did, however, not improve the correlation with vascular risk factors or radiological markers of small-vessel disease.
Similar to the WM hyperintensities discussed above, clinical-radiological correlation studies of CMBs are rare and often produce partially conflicting data [33] [34] [35] . The prevalence of microhaemorrhages is higher in VaD (65 %) than in MCI (20 %) or AD (18 %) using T2*w imaging [30] . An SWI study at 3 T principally replicated these results [36] as follows: VaD (86 %), DLB (54 %), AD (48 %), MCI (41 %) and clearly less commonly in FTLD (27 %) and subjective cognitive complaints (22 %). SWI detected more microhaemorrhages than T2*, as expected from previous studies cited above. Although the number of CMBs is increased in MCI, it is less clear whether CMB load may predict further cognitive decline. Whereas the frequency of CMBs at baseline did not differ between controls and MCI (11 % and 14 % respectively), cases with more than three microhaemorrhages were found only within the progressive MCI group [33] . Another study found that only one of 23 stable MCI but 8 of 26 progressive MCI had more than one CMH at baseline [34] . Yet another study found a higher rate of CMBs in MCI (0.6±0.9) than in controls (0.2±0.5), yet the number of microhaemorrhages did not discriminate stable versus progressive MCI. In summary, these findings indicate a detrimental effect of CMBs [37] .
Concerning the radiological-histopathological correlation of CMB, available data are also rare, again similar to the WM hyperintensities discussed above. The prevalence of CMBs on histopathology is around 60-70 % in the age group above 80-85 years [38, 39] . The radiological studies discussed above reported lower rates of CMBs on imaging (although admittedly the age was a little lower in some studies), indicating that neuroimaging may have some false-negative results. The few available radiological-histopathological correlation studies of CMBs also demonstrate false-positive results of neuroimaging. For example, one T2* study found true-positive radiologicalhistopathological correlation in 21 of 34 lesions (62 %), whereas haemosiderin deposits were noted without MR signal changes in two (of 11) brains (false negatives 18 %) [40] .
Another more recent study assessed SWI CMBs in a preselected sample of dementia patients with cerebral amyloid angiopathy [41] . Of the 38 SWI CMBs, the authors identified 7 small cavities, 1 dissection in the wall of a grossly distended vessel and 1 microaneurysm (7+1+1=24 % false negatives). The authors concluded that "…the underlying pathologic lesions we discovered correlating to (MRI) hypointensities were quite varied" [41] . In conclusion, CMB "mimics" include micro-dissection, microaneurysm, microcalcifications and arteriolar pseudocalcification [40] [41] [42] .
The most important differential diagnoses of multiple microbleeds include cerebral amyloid angiopathy (CAA), multiple (micro-)cavernomas and haemorrhagic diffuse axonal injury (DAI), which will be only very briefly discussed in the context of the current review on dementias. CAA is characterised by multiple microbleeds typically at the greywhite matter junction in a parieto-occipital lobar distribution sparing the basal ganglia and infratentorial regions. Multiple familial (micro-)cavernomas can usually be identified, as at least one cavernoma is large enough to create the typical "pop-corn" image on T2w imaging. Radiation-induced multiple micro-cavernomas can be identified on the basis of the patient's history. Finally, traumatic haemorrhagic DAI can again be identified on the basis of the clinical context and eventually other traumatic lesions such as fractures or subdural haematomas.
Today, there are no generally accepted guidelines concerning the interpretation of CBMs, for example how many CMBs are considered normal for a given age group, or whether some locations of CMBs might be clinically more relevant than other locations. Again, in agreement with the WM hyperintensities discussed above, future correlative studies are needed to improve our understanding of the diagnosis and nature of small regions of signal loss on T2* and SWI sequences.
Nuclear medicine: molecular imaging
The marker most commonly used is PET imaging of brain metabolism, using FDG as a tracer. This technique shows typical hypometabolic patterns in different dementia syndromes, as shown in Figs. 1, 2, 3 and 4 , with an overall superior sensitivity than hypoperfusion assessment by SPECT [43] . A second molecular marker used for the differential diagnosis of dementias is dopamine transporter imaging, mainly by SPECT and 123 I-ioflupane (see Fig. 3 ). Over the last decade, specific nuclear medicine tracers able to visualise in vivo amyloid plaques, which represent an important pathological hallmark of AD, have been tested and validated in humans. Most amyloid imaging investigations published to date have used 11 C-Pittsburgh compound B (PiB) as a tracer [44] . This tracer has been proven to be able to bind fibrillary amyloid with a good correlation with post-mortem measures [45] . Newer 18 F-labeled compounds, which have been recently patented, are also becoming available, and will presumably have a wider diffusion in clinical practice, owing to their greater availability. This is linked to the longer half-life of the isotope: whereas 11 C has a half-life of 20 min, needing an onsite cyclotron for production of the tracer, 18 F has a half-life of 110 min and therefore the tracer can be produced off-site.
In recent years, many studies have investigated the use of amyloid imaging markers. Excellent correspondence was demonstrated between ante-mortem amyloid PET imaging findings and Aβ deposition in the brain at autopsy [46] . A consistent finding across different studies is that around 30 % of cognitively normal elderly subjects have abnormal findings on PET amyloid imaging studies, which matches quite well the proportion of cognitively normal elderly subjects with an autopsy diagnosis of AD [47, 48] . These individuals are presumably at risk of subsequently developing dementia, a risk possibly modulated by their neurocognitive reserve potential. A recent multicentre European study on amyloid PET imaging in MCI and AD has shown that none of the MCI amyloid-negative patients converted to AD, indicating that this imaging method has an excellent negative predictive value for progression to AD [49] . These tracers will mainly be used for confirming a diagnosis of AD when clinically suspected, for early diagnosis in MCI subjects, and for differential diagnosis with other forms of amyloid-negative dementia, such as FLTD [50] .
Specific tracers also exist that are able to visualise both amyloid and tau aggregates, which are the other major histopathological hallmarks of AD [51] , or tau aggregates alone [52] , but clinical experience with these tracers is still quite limited.
Molecular imaging by radioactive tracers also allows other phenomena to be explored, such as neuroinflammation, which occurs in some forms of dementia [53, 54] , or specific neurotransmission systems, such as the cholinergic [55, 56] , serotonergic [57] and the previously mentioned dopaminergic system, among others. The discussion of these applications, which are still limited to research settings for the moment, goes beyond the scope of this review.
Advanced image analyses
Although there are currently no generally accepted diseasemodifying treatments for AD, several promising candidates are currently being evaluated (for review, see Nitsch and Hock [58] and Duara et al. [59] ). Early treatment is probably more beneficial in stopping or at least slowing down the progressive neurodegeneration than treatment of clinically overt dementia at a late stage [60, 61] . This implies the need for early diagnosis parameters including neuroimaging, and explains the interest in MCI, which was initially perceived as a prodromal state of AD [62] . The concept of MCI has evolved in recent years and now represents a heterogeneous group of various subtypes of MCI, with different progression rates of the various MCI subtypes [62] [63] [64] [65] .
Note that without further preselection, only about half of MCI subjects will progress to AD, whereas the other half remain stable or may even improve. This is problematic for early treatment of MCI individuals (half of MCI individuals may be treated despite the fact that they would remain stable even without treatment) as well as for clinical trials. For a typical placebo-controlled trial, 50 % of MCI patients remain stable even without treatment. Only 25 % of cases are progressive MCI and obtain the active medication. On the other hand, 25 % of cases are stable MCI and remain stable despite being in the placebo group. This explains why it is extremely difficult to demonstrate a beneficial drugrelated effect in unselected MCI cases.
This need for early detection of at-risk patients led to the creation of the Alzheimer Disease Neuroimaging Initiative (ADNI) [66] , the first large multicentre study with standardised MR imaging parameters, also including additional neurocognitive and other (serology etc.) assessments. The data are shared via the Internet with research groups all over the world, and this has led to multiple publications that have significantly improved the understanding of the progression of neurodegeneration as well as new image analysis tools, amongst others. This project also led to several currently on-going offspring studies, such as its European equivalent AddNeuroMed [67] . The ADNI project has led to a standardisation of MR imaging parameters, and many centres today use the ADNI imaging parameters even for clinical assessment of patients not enrolled in studies.
Advanced image analysis techniques concerning this topic are based on the assumption that subtle and systematic changes in brain structure already exist during the early phase of neurodegeneration, yet these changes are too subtle to be detected by standard visual inspection of the MRI and are detectable only by advanced image analysis techniques such as voxel-based morphometric (VBM) analysis of grey matter (GM) [68] , e.g. in MCI [69] [70] [71] [72] [73] [74] , or DTI-based analysis of WM, e.g. implementing voxel-wise tract-based spatial statistical analysis (TBSS) [75] , e.g. in MCI [76] [77] [78] [79] [80] [81] [82] [83] [84] . Most of these advanced image analysis studies used group-level comparisons, comparing typically patients with MCI versus controls and/or AD. Although such studies detect the spatial distribution of structural brain alterations during neurodegeneration, these group-level results cannot be transferred to the detection of individual patients in a clinical context. This has led to a fundamental shift in the paradigm and the application of classification analyses. The basic principle of such classification analyses can be explained with the example of face recognition. Although on average, two groups of persons might have the most pronounced group-level differences for example at the tip of the nose, it is not possible to detect an individual face only using this single parameter ("feature" in the terminology of classification analyses). On the other hand, individual faces can be recognised by a specific pattern, which combines multiple features (such as ears, lips, eyes etc.) although each feature per se is not necessarily significantly different between groups (see Haller et al. for a review [85] ). Support vector machines (SVM) [86] are a currently frequently implemented technique as the specific properties of this classification technique are well adapted to neuroimaging data. Note, however, that multiple other classification techniques exist and that the field is rapidly evolving, indicating that other classifiers may provide better or more robust results and replace the currently most commonly implemented SVM classifier in the future. The discrimination between stable versus progressive MCI based on SVM classifiers was possible with an accuracy of 85-90 % using GM [87] [88] [89] , 90-95 % using WM DTI [83, 84] and 85 % using iron deposition SWI [35] . Moreover it is possible to classify the different MCI subtypes with very high accuracy [90] . Assuming that different MCI subtypes best respond to different treatment options, this MCI subtype classification may be relevant in order to ascertain the optimal treatment at an individual level.
Current projects aim to combine multiple imaging techniques (sometimes with other parameters such as cerebrospinal fluid analysis, electroencephalography etc.) with the aim of further improving the classification accuracy and in particular the robustness of classification of for example MRI data acquired on different MRI machines at different field strengths. Although the concept of combining multiple imaging techniques is evident and straightforward, the technical implementation and in particular optimising the combination of multiple classification parameters are much more challenging [85] . One example is a recent study demonstrating that the combination of DTI-derived structural connectivity and resting-state fMRIderived functional connectivity did indeed improve classification accuracy [91] .
As many patients undergo MR imaging for clinical reasons, notably to exclude other diseases, these advanced image analysis techniques in principle reuse existing MRI data as long as standard imaging protocols are adopted. In order to be clinically useable in daily routine practice, these classification methods must be optimised and adapted to routine clinical neuroradiological use. Current developments include software installations directly implemented on the MRI machine or cloud-based solutions evaluating individual cases uploaded via the Internet to provide automated evaluation of individual patients. Currently, these solutions still require technical improvements and validation for medico-legal approval before they can be used in clinical routine.
For FDG-PET techniques the region-wise or voxel-wise comparison of individual PET images, normalised to the global uptake or to the uptake in a preserved region (often the cerebellum is chosen for this purpose) with a database of PET images acquired in healthy, ideally age-matched, individuals, is an important advance in image analysis, which already plays a relevant role in clinical practice. Such analyses provide maps of significant deviations from the normal population. The examples provided in Figs. 1 and 4 show the added value of this analysis: it clearly depicts patterns of reduced metabolism and limits subjectivity in image interpretation. Various research and commercial software tools are available for this purpose, providing complementary approaches to this problem (regionbased analyses, automated classification, etc.) and have been tested in numerous clinical studies [92] [93] [94] [95] [96] .
Neurocognitive reserve mechanisms and imaging biomarkers
Owing to individual predisposition, education, social context and other factors, some individuals may maintain normal cognitive functions longer than other individuals despite a similar degree of neurodegeneration-or from the other perspective, the same amount of neurodegeneration may lead to a variable degree of clinical cognitive decline, as first described in 1968 [97] . Various neuroimaging studies have documented a reserve phenomenon in dementias, mainly in AD, but also in other dementia types such as FTD or DLB, showing an association between education, occupation, socioeconomic status and measures of an on-going neuropathological process, such as brain atrophy, reduced brain perfusion and metabolism, or increased amyloid deposition, when correcting for clinical and neuropsychological severity [98] [99] [100] [101] [102] [103] . These observations may explain the sometimes poor correlation between neuroimaging biomarkers and cognitive function and should be taken into account when interpreting such biomarkers as a potential constraint for all advanced analysis techniques.
Conclusions
The radiologist needs to be aware that many forms of dementia have typical patterns of focal brain atrophy. Attentive visual inspection of focal atrophy may sometimes contribute to the diagnosis of a specific form of dementia, leading neuroimaging beyond the pure exclusion of other diseases. Nevertheless, radiologists should be aware of the inter-individual variation in the neurocognitive reserve, meaning that the same amount of brain pathological features will lead to a variable degree of cognitive symptoms depending on individual factors, education, social integration etc. Standardised imaging protocols using both "standard imaging techniques" and advanced sequences or molecular imaging together with multiple new advanced data analyses are currently being evaluated, and may in the near future contribute to the computer-aided early diagnosis of subtle brain structural changes at an individual patient level. Thus we may see what is at the moment still "invisible" during primary radiological inspection. The radiologist should be able to contribute to an early diagnosis of cognitive decline that will help to select at-risk patients for clinical trials in order to improve patients' outcomes.
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Editor's note Readers will notice that this issue contains two rather similar review articles on the imaging of dementia. Both articles try to help the average radiologist identify key features which may require expert neuroradiological attention. Two groups spontaneously submitted a review article at roughly the same time. There were merits in both papers; both were favourably reviewed. It was an impossible editorial choice to select one paper over another and hence both are published alongside each other. It will be interesting to see whether the astute readers will identify differences. Indeed this may lead to some interesting discussion in the opinion column on the journal's website.
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